BRPI0617151B8 - composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico - Google Patents

composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico

Info

Publication number
BRPI0617151B8
BRPI0617151B8 BRPI0617151A BRPI0617151A BRPI0617151B8 BR PI0617151 B8 BRPI0617151 B8 BR PI0617151B8 BR PI0617151 A BRPI0617151 A BR PI0617151A BR PI0617151 A BRPI0617151 A BR PI0617151A BR PI0617151 B8 BRPI0617151 B8 BR PI0617151B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical
complex
compounds
vectored
Prior art date
Application number
BRPI0617151A
Other languages
English (en)
Portuguese (pt)
Inventor
Port Marc
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Publication of BRPI0617151A2 publication Critical patent/BRPI0617151A2/pt
Publication of BRPI0617151B1 publication Critical patent/BRPI0617151B1/pt
Publication of BRPI0617151B8 publication Critical patent/BRPI0617151B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0617151A 2005-10-07 2006-10-09 composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico BRPI0617151B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0510289 2005-10-07
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US73475605P 2005-11-09 2005-11-09
US60/734,756 2005-11-09
PCT/EP2006/067214 WO2007042506A1 (en) 2005-10-07 2006-10-09 Compounds comprising short aminoalcohol chains and metal complexes for medical imaging

Publications (3)

Publication Number Publication Date
BRPI0617151A2 BRPI0617151A2 (pt) 2011-07-12
BRPI0617151B1 BRPI0617151B1 (pt) 2020-08-11
BRPI0617151B8 true BRPI0617151B8 (pt) 2021-07-27

Family

ID=36636179

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0617151A BRPI0617151B8 (pt) 2005-10-07 2006-10-09 composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico

Country Status (16)

Country Link
US (1) US8114863B2 (https=)
EP (2) EP1931673B1 (https=)
JP (2) JP5317270B2 (https=)
KR (2) KR101440761B1 (https=)
CN (2) CN101305006B (https=)
BE (1) BE2024C510I2 (https=)
BR (1) BRPI0617151B8 (https=)
CA (1) CA2625207C (https=)
DK (1) DK1931673T3 (https=)
ES (2) ES2519369T3 (https=)
FI (1) FIC20240003I1 (https=)
FR (2) FR2891830B1 (https=)
NL (1) NL301259I2 (https=)
PL (1) PL1931673T3 (https=)
PT (1) PT1931673E (https=)
WO (1) WO2007042506A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
CN103732595B (zh) * 2011-08-17 2017-02-08 默克及其合伙人公司 叶酸的白蛋白‑结合实体缀合物
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
CN105142649A (zh) * 2013-04-26 2015-12-09 法国加柏公司 造影剂配制品与有关制备方法
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
HRP20210061T1 (hr) * 2015-12-10 2021-03-05 Bracco Imaging S.P.A Dimerna kontrastna sredstva
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
US11007283B2 (en) * 2016-04-13 2021-05-18 Bracco Imaging S.P.A. Contrast agents
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
JP7258753B2 (ja) 2016-12-21 2023-04-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ Ｍｒｉイメージング剤として好適なテトラアザビシクロ大員環系マンガンキレート化合物
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
EP3728168B1 (en) * 2017-12-20 2022-03-30 General Electric Company Anionic chelate compounds
PT4151637T (pt) 2018-08-06 2025-03-26 Bracco Imaging Spa Agentes de contraste à base de pcta que suportam gadolínio
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
KR102588221B1 (ko) * 2020-07-16 2023-10-13 게르브 2-브로모글루타르산 디에스테르를 합성하는 방법
KR20230041007A (ko) 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
WO2024049087A1 (ko) * 2022-09-01 2024-03-07 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
US20240325574A1 (en) * 2023-04-03 2024-10-03 Molecular Theranostics, Llc Extradomain b fibronectin targeting peptides and derivatives for cancer imaging and therapy
EP4464708A1 (en) 2023-05-17 2024-11-20 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
TW202510874A (zh) 2023-09-01 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種大環化合物及其用途
CN118791488B (zh) * 2024-09-14 2024-11-15 成都施贝康生物医药科技有限公司 化合物、螯合物及其在磁共振成像中的应用
CN118834263B (zh) * 2024-09-14 2024-12-03 成都施贝康生物医药科技有限公司 含短氨基醇链的化合物及其金属络合物和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag, 13353 Berlin 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
DE69230970T2 (de) 1991-12-10 2001-01-04 The Dow Chemical Co., Midland Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
ES2156143T3 (es) * 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
EP1203026A4 (en) 1999-07-29 2005-03-16 Dyax Corp BINDING CENTERS FOR FIBRIN
AU2001236485A1 (en) * 2000-01-21 2001-07-31 Mallinckrodt, Inc. Novel orthogonally protected amino acid chelators for biomedical applications
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
JP2007512321A (ja) 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
JP2007516288A (ja) 2003-12-23 2007-06-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属キレート剤として有用な新規化合物
WO2006002873A2 (en) 2004-07-02 2006-01-12 Bracco Imaging Spa 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Also Published As

Publication number Publication date
PL1931673T3 (pl) 2012-11-30
BRPI0617151A2 (pt) 2011-07-12
EP1931673B1 (en) 2012-08-29
JP5731572B2 (ja) 2015-06-10
JP5317270B2 (ja) 2013-10-16
FR24C1006I1 (fr) 2024-04-19
FR24C1006I2 (fr) 2025-02-07
FIC20240003I1 (fi) 2024-02-26
KR20140060565A (ko) 2014-05-20
BRPI0617151B1 (pt) 2020-08-11
JP2013209400A (ja) 2013-10-10
CN103224495B (zh) 2015-07-15
EP2457914A1 (en) 2012-05-30
KR20080080495A (ko) 2008-09-04
WO2007042506A1 (en) 2007-04-19
BE2024C510I2 (https=) 2026-01-14
EP1931673A1 (en) 2008-06-18
ES2519369T3 (es) 2014-11-06
CA2625207A1 (en) 2007-04-19
EP2457914B1 (en) 2014-08-06
CA2625207C (en) 2014-05-13
DK1931673T3 (da) 2012-10-08
ES2390092T3 (es) 2012-11-06
JP2009513574A (ja) 2009-04-02
US20090169479A1 (en) 2009-07-02
US8114863B2 (en) 2012-02-14
KR101440761B1 (ko) 2014-09-17
CN101305006B (zh) 2013-04-24
FR2891830A1 (fr) 2007-04-13
PT1931673E (pt) 2012-09-24
FR2891830B1 (fr) 2011-06-24
CN101305006A (zh) 2008-11-12
CN103224495A (zh) 2013-07-31
NL301259I2 (nl) 2024-03-25

Similar Documents

Publication Publication Date Title
BRPI0617151B8 (pt) composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
ES2526544T3 (es) Derivado de ácido aminocarboxílico y uso médico del mismo
Ono et al. Push–pull benzothiazole derivatives as probes for detecting β-amyloid plaques in Alzheimer’s brains
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
WO2009155017A3 (en) Novel substituted azabenzoxazoles
Patil et al. Curcumin targeted, polymalic acid‐based MRI contrast agent for the detection of Aβ plaques in Alzheimer's disease
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
JP2012102106A5 (https=)
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
US20110071301A1 (en) Abeta-binding small molecules
MX2008014898A (es) Composicion para el diagnostico de enfermedades relacionadas con amiloides.
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
EP2098522A4 (en) NEW CONNECTION WITH AFFINITY TO AMYLOID
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EP2022792A8 (en) Novel compound having affinity to amyloid
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
CO6210702A2 (es) Derivado de pirazolopirimidina
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
Joubert et al. Small molecule fluorescent ligands as central nervous system imaging probes
RU2012136457A (ru) Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad)
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
RU2009118486A (ru) Хелаты металлов, имеющие перфторированный пэг радикал, способы их получения и их применение
Hausner et al. Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene
US12404291B2 (en) Antimicrobial agent

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO